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Received 3 March 2010; received in revised form 23 June 2010; accepted 22 July 2010Abstract Here, we have prospectively isolated and characterized, for the first time, clonogenic cells with self-renewal
capacities from mantle cell lymphoma (MCL), a particularly deadly form of non-Hodgkin's lymphoma (NHL). Self-renewal and
tumorigenic activities were enriched in MCL cell fractions that lacked expression of the prototypic B-cell surface marker,
CD19. CD45+CD19- cells represented a relatively small fraction of the total MCL tumor cells; however, they recapitulated
the heterogeneity of original patient tumors on transplantation into immunodeficient mice. As few as 100 of these cells
displayed self-renewal capacities in secondary and tertiary recipient mice by in vivo limiting dilution assays. Similar to
leukemic stem cells, CD45+CD19- MCL cells also displayed a quiescent status as determined by dye efflux assays. In
summary, this study is the first to isolate subpopulations of MCL cells that have self-renewal and tumorigenic capacities.
Identification and characterization of MCL-ICs are important first steps toward understanding how self-renewal and
tumorigenicity are regulated in MCL and designing targeted therapies against MCL-ICs will ultimately lead to improved
outcomes for MCL patients.
© 2010 Elsevier B.V. All rights reserved.Introduction
Various reports have identified cancer-initiating cells (C-ICs)
as important mediators for tumor growth, progression, and
metastasis (Hajj et al., 2003; O'Brien et al., 2007; Lapidot et
al., 1994; Singh et al., 2004; Matsui et al., 2004; Hermann et
al., 2007). Furthermore, C-ICs are also largely resistant to⁎ Corresponding author. 1835 Pressler Street, IMM-630F, University
of Texas–Health Science Center at Houston. Houston, TX 77030,
USA. Fax: +1 713 500 2424.
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doi:10.1016/j.scr.2010.07.003conventional chemotherapy and radiotherapy, suggesting
that these resistant cells may be responsible for tumor
recurrence (Jordan, 2004; Bao et al., 2006; Dean et al.,
2005; Diehn and Clarke, 2006; Woodward et al., 2007). Early
studies demonstrated the presence of clonogenic tumor cell
populations with stem-like properties in NHL, which pre-
sumably arise from B cells of origin (Tweeddale et al., 1987;
Jones et al., 1979; Bobak and Whisler, 1980). However, the
identities of these cell types that contribute to tumorige-
nicity in vivo have remained obscure. Transplantation of
normal and leukemic human hematopoietic stem cells into
immunodeficient mice is a bona fide way to measure in vivo
long-term repopulating activities (Lapidot et al., 1997; Dicks.
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Figure 1 Isolation of CD45+CD19- and CD45+CD19+ MCL cells. (A) FACS analysis of patient samples used for isolation of clonogenic
MCL populations. Note that CD19+CD20+ cells are markedly increased in all eight MCL samples compared to normal PBMC. Percentages
of CD19+CD20+ cells were calculated based on isotype control for each patient, and CD3+ and CD34+ cells were removed prior to FACS
analyses. (B) Highly purified MCL cells were used for xenograft transplantation. CD3+ T cells and CD34+ HSC were removed by
immunodepletion prior to sorting. There were no detectable CD3+ and CD34+ cells present after depletion. Postsort analysis of
CD45+CD19- cells showed nearly 99–100% of desired populations. All cells were gated for CD45+ cells prior to CD19 separation, and
gates were determined using IgG isotype controls.
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Figure 1 (continued).
214 Z. Chen et al.et al., 1997). By using the xenotransplantation assay system,
we attempted to identify a subpopulation of cells that
initiate and sustain tumor growth in human MCLs.MCL is a subtype of B-cell NHL, and accounts for approx-
imately 6%of all NHLcases (Campoet al., 1999; Swerdlowet al.,
2001; Salaverria et al., 2005). Themajor characteristic ofMCL is
215Cancer stem cells in mantle cell lymphomat(11:14)(q13:q32) translocation that leads to the increased
level of cyclin D1 (CCND1) expression. This is caused by the
juxtaposition of the cyclin D1 gene to B-cell immunoglobulin
heavy chain transcriptional enhancers. However, transgenic
mice overexpressing wild-type CCND1 in their B cells do not
show increased lymphoma incidence (Adams et al., 1999;
Bodrug et al., 1994). These data indicate that CCND1 over-
expression is necessary, but not sufficient to induce MCL. The
cellular morphology of MCL at the time of diagnosis is irregular
nuclei, condensed chromatin, and scant and pale cytoplasm
with up-regulated cell surface markers such as CD20 and CD79a
(Campo et al., 1999; Swerdlow et al., 2001; Salaverria et al.,
2005). Most MCL display widespread cellular heterogeneity in
advanced stages, which contributes to a poor response to
therapies (Salaverria et al., 2005; Sweetenham, 2009; Ruan et
al., 2009). The heterogeneity within MCL tumors and resistance
to therapies imply that the MCL tumors comprise cells with
different tumorigenic capacities. In addition, unlike other B-cell
lymphomas,mostMCLdonot undergo somatic hypermutation in
the immunoglobulin heavy chains (Kienle et al., 2003). All these
combined biological properties indicate that MCL could arise
from the early-stage B cells, rather than from the committed B
cells in germinal centers.
Herewe report thatMCL-initiating activities are enriched in
a subpopulation of tumor cells that lack the prototypic B-cell
marker, CD19. As few as 100 CD45+CD19- MCL cells displayed
self-renewal activities and formed tumors in immunodeficient
mice. In contrast, CD45+CD19+ MCL cells were not able to self-
renew during serial transplantation assays and displayed
greatly reduced tumorigenicity. These data demonstrate
that MCL tumors comprise hierarchical cells with different
tumorigenic capacities. Identification of clonogenic MCL-
initiating cells provides valuable tools for understanding the
pathogenesis of MCL in humans.Results
Clinical samples used to identify mantle cell
lymphoma-initiating cells
Tumor cells were harvested via aphaeresis from patients with
clinically confirmed stage 4 MCL, with involvement of extra
nodal sites such as the intestinal tract, kidney, bone marrow,
and peripheral blood. In each sample, markedly increased
numbers of committed B cells (CD19+CD20+) were present
compared to normal PBMC samples (Fig. 1a). Prior to
transplantation into immunodeficient mice, each sample was
analyzed for the presence of Epstein-Barr virus (EBV) by PCR.
All eight patient samples (Fig. S1a) aswell as primary xenograft
tumors used for secondary transplantation (Fig. S1b) were
negative for EBV. At the time of diagnosis each sample was
positive for the t(11:14)(q13:q32) translocation, as determined
by FISH. We also confirmed elevated levels of cyclin D1 gene
expression in all patient samples by real-time PCR (Fig. S1c).Identification of markers that fractionate
tumorigenicity in mantle cell lymphoma
In order to isolate clonogenic populations in human MCL,
which we have termed MCL-initiating cells (MCL-ICs), weutilized a similar approach that has been used successfully to
isolate nonmalignant stem and progenitor cells, i.e.,
monoclonal antibody-based cell sorting followed by analysis
of the sorted cells using clonogenic assays in vitro and in vivo
(Morrison and Weissman, 1994; Baum et al., 1992; Uchida
and Weissman, 1992). Since there is no in vitro assay
available to measure clonogenicity of human B cells, we
used in vivo immunodeficient xenograft models for the
identification of MCL-ICs.
Unlike other B-cell lymphomas, most MCL do not undergo
somatic hypermutation in immunoglobulin heavy chains
(Kienle et al., 2003). These biological properties suggest
that MCL tumors likely arise from early-stage B cells, rather
than from committed B cells in germinal centers. Therefore,
we initially focused on differential expression of the cell
surface antigen, CD19, which is involved in early stages of B-
cell commitment (Hardy and Hayakawa, 2001). The levels of
CD19 expression were heterogeneous among MCL patients
with minor percentages (3–15%) of CD19-negative cells
(Table 1A). Prior to separation by CD19 expression, CD3+ T
cells and CD34+ hematopoietic stem cells (HSCs) were
depleted. No detectable T cells or HSCs were present in
MCL tumors after depletion (Fig. 1b). Postsort analyses of
injected cells showed nearly 100% purity of the desired
population (Fig. 1b).
Surprisingly, CD45+CD19- MCL cells generated MCL-like
tumors in all NOD/SCID mice tested (Table 1B, Fig. S1d).
MCL-like tumors were detected in the peritoneum of the
abdominal wall, lymph nodes, spleens, or thymus, indicating
that residual lymphoid tissues in NOD/SCID mice can support
lymphoma growth (Fig. S1d). In contrast, mice injected with
CD45+CD19+ MCL cells did not establish tumors in the same
time period (Table 1B).In vivo limiting dilution assays reveal that at least
one in 100 CD45+CD19- MCL-ICs possess
tumor-initiating activities
To quantify self-renewal activities of CD45+CD19- cells, we
performed limiting dilution assays, which are in vivo
bioassays that detect positive or negative responses in
mice receiving varying doses of injected cells (Taswell,
1984; Taswell, 1981; Strijbosch et al., 1987). CD45+CD19-
and CD45+CD19+ cells were isolated and tested from all eight
patient samples. All mice (n=57) injected with CD45+CD19-
cells developed MCL-like tumors. In contrast, mice injected
with CD45+CD19+ cells (n=57) did not develop tumors in the
same time period, with the exception of one mouse
(Table 1B, Table S1). Since NOD/SCID mice develop
spontaneous murine thymomas and lymphomas beyond 8–
10 months of age (Chiu et al., 2002), we sacrificed the mice
injected with CD45+CD19+ cells at the same time when the
mice injected with CD45+CD19- cells succumbed to tumors.
CD45+CD19- MCL cells from eight different patients gener-
ated MCL-like tumors during serial transplantations (Table
S1). Based on the numbers of mice analyzed, we have
calculated the frequencies of stem cells in CD45+CD19- MCL
cells (http://www.bioinf.wehi.edu.au/software/elda). The
frequency of malignant stem cells within CD45+CD19-
fractions is 1 in 1 (upper limit) to 1 in 1.08×102 cells. In
contrast, the frequencies of stem cells in the CD45+CD19+
Table 1A Heterogeneous expression of CD19 in MCL patient samples
Patient # % of CD45+CD19- cells Light chain restriction in
patient samples
Light chain restriction in
CD45+CD19- xenografts
Pt 1 8 % Lambda Lambda
Pt 2 10 % Kappa Kappa
Pt 3 9 % Lambda Lambda
Pt 4 3 % Lambda Lambda
Pt 5 15 % Kappa Kappa
Pt 6 11 % Kappa Kappa
Pt 7 10 % Lambda Lambda
Pt 8 7 % Lambda Lambda
The percentages of CD45+CD19- cells were calculated based on expression levels with IgG isotype control (not shown). CD3+ and CD34+ cells
were separated from mononuclear cells of each sample as described under Materials and methods. All CD45+CD19- xenograft tumors
displayed the same light chain restriction patterns as the original patient cells. Intracellular stainings were performed to analyze light
chain restriction patterns as described under Materials and methods. CD45+CD19- xenograft tumors displayed the same light chain
restriction patterns that match the original patient tumor cells.
216 Z. Chen et al.cells are 1 in 7 109 449 (upper limit) to 1 in 3.46×108 (lower
limit). Therefore, CD45+CD19- cells are enriched with stem-
like cells between 3.2×106-fold and 7×106-fold as compared
to CD45+CD19+ MCL cells.
To ensure that reduced tumor engraftment of CD45+
CD19+ cells is not due to inhibitory effects of anti-CD19
antibodies, as has been reported in immunodeficient mice
engrafted with human leukemic cells after anti-CD38Table 1B Kaplan-Meier curves
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Kaplan-Meier curve illustrating the proportion of survival of NOD/
SCID mice injected with various doses of CD45+CD19+ or CD45+
CD19- MCL-ICs cells. All mice (n=57) injected with CD45+CD19-
cells developed MCL-like tumors and were sacrificed due to tumor-
related abnormalities. The time to succumb to the tumors differed
depending on the doseof injected cells.Mice implantedwithCD45+
CD19+ fractions did not develop tumors within the range of injected
cells (5×106 to ~100 cells, n=56 of 57) and in the time course tested,
except for one mouse in passage 2 (see Table S1).antibody incubation (Taussig et al., 2008), we incubated
MCL tumor cells with anti-CD19 antibodies, F(ab′)2 frag-
ments of CD19 antibodies, and isotype controls prior to
transplantation into the mice. All MCL tumor cells were
equally tumorigenic regardless of presence of anti-CD19
antibodies (Table 2A and Fig. 2). In addition, CD122 antibody
injection to NOD/SCID mice did not change engraftment of
MCL cells (Table 2B). Therefore, reduced engraftment of
CD45+CD19+ MCL cells in NOD/SCID mice is not due to
inhibitory effects of CD19 antibodies mediated by innate
immune system of the immunocompromised mice.
CD45+CD19- xenografts generate the cellular
heterogeneity of original patient samples
To determine whether CD45+CD19- xenograft tumors resem-
bled the original tumors, we first examined intracellular
light chain restriction patterns in xenograft tumors. Human B
cells use V(D)J recombination to assemble genes for the
variable regions of the heavy and light chains of antibodies.
The result is either kappa or lambda light chain generation
(Tonegawa, 1983). CD45+CD19- xenograft tumors from all
eight patients displayed the same light chain restriction
patterns as the original patient samples (Table 1A). We
further analyzed cell surface antigen expression of CD45
+CD19- xenograft tumors by FACS analyses using various
makers important for the development of normal and
malignant B cells. CD45+CD19- xenograft tumors showed
comparable levels of cell surface marker expressions in
comparison to the original patient samples (Fig. 3a). Cells
containing the defining genetic hallmark of MCL, t(11;14)
(q13;q32) translocation, were detected in original patient
tumors as well as in xenograft tumors derived from CD45+
CD19- MCL cells (Fig. 3b). We also compared histological
characteristics of CD45+CD19- xenograft tumors with original
patient tumor cells. Xenografts injected with unfractionated
patient cells (termed unfractionated xenograft tumors) were
also compared due to the lack of whole lymph node biopsies
from patients. CD45+CD19- xenografts and unfractionated
xenografts exhibited similar pathological characteristics by
H&E staining, including small to medium-sized lymphoid cells
with irregular nuclear contours (Campo et al., 1999;
Swerdlow et al., 2001) (Fig. 4a). Both xenograft tumors
Table 2A Anti-CD19 antibodies do not inhibit engraftment of MCL tumor cells in NOD/SCID mice
Cells injected Cell dose # of mice tested Total # of mice have tumors
MCL tumor cells (pt1, pt3, pt8) + anti-CD19 antibodies 5×106 5 5/5 (100%)
MCL tumor cells (pt1, pt3, pt8) + IgG antibodies 5×106 3 3/3 (100%)
MCL tumor cells (pt1, pt3, pt8) + (Fab)2 fragments of CD19 5×106 4 4/4 (100%)
MCL patient cells were incubated with anti-CD19 antibodies, isotype controls, and F(ab′)2 fragments of anti-CD19 antibodies before
transplantation into NOD/SCID mice by intraperitoneal injection. F(ab′)2 fragments of anti-CD19 antibodies were generated by enzymatic
digestion using ficin (Pierce) and then purified using a protein A column to remove Fc portions. MCL-like tumors formed at equal frequency in
all mice.
217Cancer stem cells in mantle cell lymphomashowed increased expression of human CD20, CD19, CD45,
and cyclin D1 by immunohistochemistry (Fig. 4a). The
proliferative antigen, Ki-67, was highly expressed in CD45
+CD19- xenograft tumors, unfractionated xenograft tumors,
and in patient cells (Fig. 4a). Together, these data
demonstrate that CD45+CD19- MCL cells, even though they
represent relatively small populations within MCL tumors,
are able to generate xenograft tumors that recapitulate
heterogeneity of original patient tumors.
Since mice injected with CD45+CD19+ cells did not
develop intraperitoneal tumors in the time course analyzed,
we examined organs for the expression of human cyclin D1
and CD19. The livers of CD45+CD19+ xenografts were largely
negative for cyclin D1 and CD19, although small patches of
splenocytes with low CD19 expression were noted (Fig. 4b).
In contrast, obvious cyclin D1 expression was detected in
spleens isolated from all CD45+CD19- xenografts, but not in
spleens of mice injected with CD45+CD19+ cells (Fig. S2a).
Various organs such as brain, heart, liver, spleen, and
intestine from CD45+CD19+ xenograft mice were mostly
negative for human lymphocytes, as revealed by anti-CD45
immunostaining (Fig. S2b). In contrast, CD45-positive cells
engrafted into the liver, spleen, and intestine of CD45+CD19-
xenograft mice. All xenograft mice (Table S1) were analyzed
by FACS and/or immunohistochemistry and showed similar
expression patterns.Fitc-IgG
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Figure 2 Anti-CD19 antibodies do not inhibit engraftment of MCL t
from mice transplanted with MCL cells after incubation with eitherCollectively, our data suggest that we have successfully
divided MCL tumors into two fractions: one is enriched for
self-renewal and tumor-initiating activities, whereas the
other lacks self-renewal capacity and displays greatly
reduced tumorigenicity in immunodeficient mice.
Hematopoietic stem cells are not the sources of
tumorigenicity
MCL patient cells contained less than 1% CD34+ cells (Figs. 1b
and S3a). To ensure that the self-renewal and tumorigenic
activities of MCL-ICs were not from CD34+ cells, we further
fractionated CD45+CD19- cells based on CD34 expression.
Both CD45+CD19-CD34+ and CD45+CD19-CD34- cells were
equally tumorigenic in all mice tested (n=6) and all tumors
developed with similar kinetics (Fig. S3b). Therefore,
hematopoietic stem cells in MCL samples do not contribute
to the stem-like properties of MCL-ICs.
Other cell surface markers do not fractionate
tumorigenicity
We also fractionated MCL tumors using additional cell surface
markers that play established roles in B-cell development to
determine whether these markers could enrich for tumorigenicD45
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Table 2B Treatment of immunosuppressive antibodies to NOD/SCID mice does not influence engraftment of MCL tumor cells
Cells injected Cell dose # of mice tested Total # of mice have tumors
MCL tumor cells (pt1, pt3) + anti-CD19 antibodies
Injected into anti-CD122 treated NOD/SCID mice
5×106 5 5/5 (100%)
MCL tumor cells (pt1, pt3) + IgG antibodies Injected
to anti-CD122-NOD/SCID mice
5×106 2 2/2(100%)
CD122 antibody (200 μg) was administrated by intraperitoneal injection on the day before transplantation. MCL tumor cells incubated with
anti-CD19 or isotype control were injected into anti-CD122-treated NOD/SCID mice. Both populations formed MCL-like tumors in all mice
tested.
218 Z. Chen et al.properties ofMCL-ICs (Blomand Spits, 2005; Kondo et al., 2001).
The expressions of some of these markers, such as CD5, were
heterogeneous between patients (Fig. S3c). Both CD3+ T cells
and CD34+ HSC cells were also depleted prior to sorting, as
shown in postsort analyses (Fig. S3d). None of the markers
tested, however, fractionated tumorigenicity similar to CD19
expression (Fig. S3e). All xenograft tumors generated withCD45+CD19- 
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219Cancer stem cells in mantle cell lymphomanot be an appropriate source for isolation of clonogenic cancer-
initiating cells.MCL-ICs are maintained in a quiescent status
Since advanced MCL is often resistant to conventional
therapies that target the bulk of proliferating cells (Campo
et al., 1999; Swerdlow et al., 2001; Salaverria et al., 2005), we
investigated the cell cycle status of CD45+CD19- cells using
Rhodamine 123 (Rho123). DecreasedRho123 dye accumulation
reflects quiescent cellular status as well as increased ABC drug
transporter expression (Chaudhary and Roninson, 1991).
Rho123 is a substrate for P-glycoprotein (P-gp), an efflux
pump responsible for multidrug resistance in tumor cells. P-gp
contributes to drug resistance by acting as an unidirectional
drug efflux pump, resulting in decreased accumulation of
drugs within the cells (Chaudhary and Roninson, 1991; Dean et
al., 2001). Analyses of MCL tumor cells from patients showed
that CD45+CD19- fractions were enriched with decreased
Rho123 dye accumulation as compared to CD45+CD19+
fractions (Fig. 5a). However, CD45+CD19- cells were not the
only populations with decreased Rho123 accumulation. CD45
+CD38- (46%), CD45+CD10- (14%), and CD45+CD5- (5%) MCL
cells showed decreased Rho123 accumulation compared to
CD45+CD38+, CD45+CD10+, and CD45+CD5+ cells (Fig. 5b).
Given that CD38 is a marker for more differentiated
lymphocytes (Munshi et al., 2002; Prus and Fibach, 2003), it
is likely that less differentiated CD38-negative populations are
enriched with Rho123 dye efflux activities as shown in CD34
+CD38- hematopoietic stem cells (Mckenzie et al., 2007). We
are currently investigating the functional importance of
cellular quiescence in MCL initiation.
Since rhodamine efflux assays do not distinguish between
cells in different stages of the cell cycle, we further stained
MCL patient cells with Hoechst (Hst) and Pyronin Y (PY) dyes.Cells in G0 phase have diploid DNA and low RNA content and
low Hst and PY staining. As cells progress through G1 to S/G2
+M phases, they synthesize both RNA and DNA and display
more intense staining for Hst and PY (Darzynkiewicz et al.,
1979; Shapiro, 1981). Quiescent AML cells isolated according
to Hst and PY stainings can form more colonies in vitro and
also initiate AML in NOD/SCID mice (Gothot et al., 1997;
Gothot et al., 1998). CD45+CD19+ fractions were enriched
for G1 and S/G2+M phase cells (58%) and CD45+CD19-
fractions were enriched for quiescent G0 phase (Fig. 5b).
Discussion
We have successfully isolated a minor population from
mantle cell lymphoma that is highly enriched with tumor-
initiating activities. The frequencies of tumor-initiating cells
in CD45+CD19- MCL populations were 48 000-fold higher than
those in unfractionated MCL populations. In mice, CD19-
early B-cell progenitor cells possess stem-like plasticity
which enables them to differentiate into cellular lineages
other than B cells (Gothot et al., 1998). On development to
the fully committed B cells, this stem-like plasticity is lost
(Gothot et al., 1998). Therefore, it is possible that normal
CD45+CD19- cells more readily initiate MCL on genetic
mutations compared to fully differentiated CD19+ cells.
However, our report does not address whether CD45+CD19-
cells are indeed the normal cell of origin that give rise to
MCL. More detailed studies will be needed to determine if
early B-cell progenitors are the normal cell of origin for MCL
or whether a dedifferentiation process occurs, similar to
what has been reported in mice (Cobaleda et al., 2007).
However, there are significant differences between early
murine and human B-cell development; e.g., human pre-B-I
cells do not follow a proliferative expansion in response to IL-
7 (Prieyl and LeBien, 1996). Therefore, careful analyses are
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Figure 4 Immunohistochemical analysis of CD45+CD19- xenograft tumors. (A) Xenograft tumors generated from both
unfractionated and sorted CD45+CD19- tumor cells (Pt1) displayed pathological features resembling the original patient tumors.
The xenograft tumors and the patient's original tumor cells expressed comparable levels of CD19, CD20, cyclin D1, and Ki-67
proliferation antigens. Cells from patient PBMC were examined for Ki-67 and cyclin D1 expression (arrows). At least five sections from
each xenograft tumor were analyzed. Only Pt1-derived tumors are shown even though all xenograft tumors derived from eight
different patients were analyzed. Other xenograft tumors also generated similar results. (B) Immunohistochemical analysis of CD45
+CD19- and CD45+CD19+ xenograft tumors. CD45+CD19- and CD45+CD19+ xenograft tumors (Pt4) are immunostained for human CD19
and cyclin D1. Arrows in each panel indicate representative signals.
221Cancer stem cells in mantle cell lymphomanecessary to delineate the normal cell of origin for MCL.
Development of in vitro assays that can measure clonogeni-
city of human B cells will help in understanding the factors
that drive early human B cells to expand and differentiate.Conclusions
The prospective identification of MCL-ICs that initiate and
sustain tumors in human is a critical first step toward
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223Cancer stem cells in mantle cell lymphomadesigning therapeutic strategies for targeting these cells.
Additionally, isolation of MCL-ICs will allow for future studies
targeting molecular mechanisms that couple self-renewal,
tumorigenicity, and chemotherapeutic resistance in MCL.
Materials and methods
AntibodiesCommercially available antibodies were used: anti-CD45
(HI30, IgG1, k), anti-CD19 (HIB19, IgG1, k), anti-CD3 (HIT3a,
IgG2a, k), anti-CD34 (581, IgG1, k), anti-CD5 (UCHT2, IgG1, k),
anti-CD20 (2H7, IgG2b, k), anti-CD69 (FN50, IgG1, k), anti-
CD10 (HI10a, IgG1, k), anti-CD38 (HIT2, IgG1, k), anti-CD43
(L10, IgG1), and anti-CD27 (O323,IgG1, k). All antibodies were
conjugated with appropriate fluorochromes based on the
combinations of antibodies used in each experiment. Anti-
bodies were purchased from BD or ebioscience.
Tumor cell lines and patient samples
The Jeko and SP53 human MCL cell lines were cultured
and maintained in RPMI 1640 (Cellgro) supplemented
with 10% heat-inactivated fetal calf serum (Cellgro), 2 mM
L-glutamine, 50 U/ml penicillin, and 50 μg/ml streptomycin.
Blood specimens from patients were obtained after informed
consent, as approved by M.D. Anderson Cancer Center as well
as by the University of Texas–Health Science Center
Institutional Review Boards. Blood samples from nonmalig-
nant donors were purchased from Gulf Coast Regional Blood
Center (Houston, TX). Mononuclear cells were isolated from
all primary patient PBMC and normal PBMC by standard Ficoll
gradient methods.
Cell staining and sorting
Cell preparation
CD3+ T cells and CD34+ HSCs were removed from PBMC
samples prior to all analyses using lineage-specific antibodies
(CD3 and CD34, 1:500 dilutions) and magnetic beads
according to the manufacturer's protocol (Dynal). PBMC
(1×107 cells/ml) were first incubated with unlabeled CD3
and CD34 antibodies for 20 min at 4 °C with gentle rotation.
Cells were washed three times with buffer (HBSS containing
2% heat inactivated FBS). Dynal beads were added and
incubated for 30 min at 4 °C with gentle rotation. Beads
were sorted with a magnet for 3–5 min and the supernatants
were harvested (“A” fraction) for further analyses.CD45+CD19+ and CD45+CD19- MCL cell isolation
Fraction “A” was used for this experiment. The absence of
CD3+ and CD34+ cells was confirmed in the cells (“A” fractionFigure 5 CD45+CD19- MCL-ICs are maintained in a quiescent statu
ICs displayed increased rhodamine efflux activities (Rho123 low p
percentages of Rho123 low cells in patient samples are indicated in th
and PyroninY (PY) expression. Patient tumor cells (Pt1) were analyze
CD45+CD19- fractions are enriched for G0 phase cells (79%) and CD45
CD3- and CD34-positive cells were depleted prior to Rho123 stainingabove) by FACS before sorting for CD45+CD19+ and CD45+
CD19- fractions. If the “A” fraction still contains CD3+CD34+
cells, cells were sorted as follows: CD45+CD19-CD3-CD34- or
CD45+CD19+CD3-CD34-. The following antibodies were used
for FACS analyses and sorting: FITC-conjugated anti-CD45
(HI30), PE-conjugated anti-CD19 (HIB19), and APC-conjugated
CD34 (581). CD3 antibodies (HIT3a) were conjugated with
biotin, which were followed by staining with PE-Cy7 conjugat-
ed streptavidin. The prepared cell populations were incubated
for 20–30 min at 4 °Cwithgentle rotation. Stainedpopulations
were then washed three times with HBSS containing 2% FBS.
The gates were determined based on negative controls
(isotype stainings) and positive controls. Nonviable cells
were eliminated with fluoro-gold (50 μM). All fractions were
isolated by fluorescence-activated cell sorting (Aria, Becton
Dickinson, San Jose, CA). Postsort analyses were done in all
samples to ensure greater than 99% purity. If necessary, cells
were sorted twice to achieve desired sorting purities. All FACS
data were analyzed using the Diva software (Becton Dickinson)
or FlowJo (Tree Star, Ashland, OR).
Xenotransplantation assay
Immunodeficient NOD/SCID mice (2–4 weeks old) were
purchased from Jackson Labs (Bar harbor, ME). These mice
were then bred and maintained in a pathogen-free facility at
the UT–Health Science Center. All animal procedures were
approved by the UT-HSC Animal Care Committee. For all
xenograft assays, 2- to 3-month-old mice (male or female)
were used. Appropriate cell numbers and cell types were
injected by intraperitoneal injection into NOD/SCID mice
given a dose of 2.25 G using gamma rays from a cesium
irradiator. Mice were kept until they showed obvious signs of
distress or discomfort in accordance with approved guide-
lines established by the Animal Care Committee at the
UT–health Science Center. CD45+CD19- and CD45+CD19+
xenograft mice were sacrificed at the same time points
because 10% of NOD/SCID mice develop spontaneous murine
lymphoproliferative diseases beyond 8–10 months age.
Limiting dilution assays and serial transplantations
For limiting dilution assays, unsorted MCL patient cells were
injected intraperitoneally at doses ranging from 107 to 103
cells. Eight different patient samples were injected. Highly
purified CD45+CD19- and CD45+CD19+ cells (isolated as
described in the cell separation procedure) were injected
at doses ranging from 100 to 5×106 cells per mouse. Three to
seven mice per group were used for each injection dose. For
serial transplantation experiments, tumors from primary or
secondary mice were separated based on human CD45 and
CD19 expression. Prior to sorting, human CD3 and CD34 cells
were removed by antibodies conjugated to magnetic beads.
The CD45+CD19- and CD45+CD19+ cells, at doses rangings. (A) In comparison to CD45+CD19+ MCL cells, CD45+CD19- MCL-
opulations), indicative of ABC transporter activities. Relative
e boxed areas. (B) MCL-ICs are quiescent based on Hoechst (Hst),
d for CD45 and CD19 expression as well as Hst and PY stainings.
+CD19+ fractions are enriched for G1/S/G2+M phase cells (58%).
and Hst/Py.
224 Z. Chen et al.from 100 to 5×106 cells (Table S1), were then reimplanted
into irradiated secondary or tertiary NOD/SCID mice (2.25 G)
via intraperitoneal injections.
Detection of Epstein-Barr virus (EBV)
DNA was extracted using the QIAamp DNA blood mini kit
(Qiagen, Valencia, CA) according to the manufacturer's
instructions. The presence of EBV was detected by amplify-
ing fragments using the following primers: 5-CTTTAGAGGC
GAATGGGCGCCA-3 and 5-TCCAGGGCCTTCACTTCGGTCT-3.
One hundred nanograms of DNA and 150 nM of each primer
were added to 50 μl PCR supermix (Invitrogen, CA), and
94 °C for 30 s, 55 °C for 30 s, and 72 °C for 1 min with a
final extension at 72 °C for 10 min were used to amplify
the gene.
Rhodamine 123 staining
CD3+ (T cells) and CD34+ (HSCs) were removed from primary
patient samples as described above. These cells were
suspended at 106 cells/50 μl of HBSS containing 5% FBS.
Rhodamine 123 dye (Invitrogen) was added to a final
concentration of 0.1 μg/ml. Cells were incubated for
20 min at 37 °C followed by washing cells twice with HBSS.
Cells were resuspended to allow efflux at 37 °C for 2 h. Cells
were washed once with HBSS and stained with antibodies
before FACS analyses.
CD19 antibodies and engraftment
To address whether anti-CD19 antibodies influence engraft-
ment, MCL tumor cells (after CD3 and CD34-positive cell
depletion) were first incubated with test antibodies (uncon-
jugated anti-CD19, clone HIB19) or isotype control anti-
bodies (IgG1) for 30 min at 4 °C with gentle rotation.
Antibodies (0.5g) were added to 106 cells in a volume of
50 μl. The cells were then washed three times and
resuspended in phosphate-buffered saline before transplan-
tation into NOD/SCID mice. All mice were sacrificed 60 days
after injection prior to death (as described in Taussig et al.
(2008). Intraperitoneal tumors and various organs of all
xenograft mice were examined. Organs were analyzed by
immunohistochemistry for the presence of human CD45
+CD19+ cells. Intraperitoneal tumors were also examined by
FACS analysis to ensure they recapitulate heterogeneity of
original patient tumors.
Immunohistochemistry
Paraffin sections were made from xenograft tumors and slide
sections were heated at 60 °C for 20 min. Sections were
deparaffinized by standard methods (100% xylene, 100%
ethanol, 95% ethanol, 80% ethanol) and antigens were
retrieved by incubating slides in 0.1 M citrate buffer in
vegetable steamer for 30 min. After cooling down slides to
room temperature, 0.3% H2O2 was added and incubated for
10 min. After wash, slides were blocked in 10% swine serum
for 30 min followed by incubation with primary antibodies
(Ki-67, 1:150 cyclin D1, 1:100, Abcam) for 2 h. Slides werewashed and incubated with biotinylated secondary antibo-
dies (Dako). Signals were detected after incubating slides
with ABC complex (Vector lab) followed by incubation with
DAB (Vector). Counterstaining was done with Mayer's
Hematoxylin (Sigma) for 10 min at RT. Slides will be
dehydrated before pictures were taken. For Ki-67 staining
on frozen tissues, sections were incubated in Zamboni's
fixative for 10 min before antibody staining. Zamboni's
solution is parafomaldehyde, picric acid solution (pH 7.3).
Analysis of cyclin D1 translocation
Cells were fixed with FISH fixative (100% methanol:acetic
acid=3:1) for 30 min. Cells were dried in air and treated
sequentially with the following reagents. 2X SSC (pH 7.0,
37 °C) for 30 min, 1X PBS for 5 min, 1X formaldehyde for
5 min, 1X PBS for 5 min, 70% ethanol for 1 min, 85% ethanol
for 1 min, 100% ethanol for 1 min followed by dry samples in
air for 15 min. Probes specific for the CCND1 (SpectrumOr-
ange) and IGH genes (SpectrumGreen) were used to detect
translocation (11:14)(q13:q32) (Vysis). t(11:14)(q13:q32)
translocation was observed with Lieca microscope equipped
with a triple-band pass.
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